The author of 《Development of novel amides as noncovalent inhibitors of immunoproteasomes》 were Ettari, Roberta; Cerchia, Carmen; Maiorana, Santina; Guccione, Manuela; Novellino, Ettore; Bitto, Alessandra; Grasso, Silvana; Lavecchia, Antonio; Zappala, Maria. And the article was published in ChemMedChem in 2019. SDS of cas: 3395-91-3 The author mentioned the following in the article:
The development of immunoproteasome-selective inhibitors is a promising strategy for treating hematol. malignancies, autoimmune and inflammatory diseases. In this context, we report the design, synthesis, and biol. evaluation of a new series of amide derivatives as immunoproteasome inhibitors. Notably, the designed compounds act as noncovalent inhibitors, which might be a promising therapeutic option because of the lack of drawbacks and side effects associated with irreversible inhibition. Among the synthesized compounds, we identified a panel of active inhibitors with Ki values in the low micromolar or sub-micromolar ranges toward the β5i and/or β1i subunits of immunoproteasomes. One of the active compounds was shown to be the most potent and selective inhibitor with a Ki value of 21 nM against the single β1i subunit. Docking studies allowed us to determine the mode of binding of the mols. in the catalytic site of immunoproteasome subunits.Methyl 3-bromopropanoate(cas: 3395-91-3SDS of cas: 3395-91-3) was used in this study.
Methyl 3-bromopropanoate(cas: 3395-91-3) belongs to bromides. A variety of minor organobromine compounds are found in nature, but none are biosynthesized or required by mammals. Organobromine compounds have fallen under increased scrutiny for their environmental impact.SDS of cas: 3395-91-3
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary